Gastroesophageal junction adenocarcinoma Trials in Houston, United States
Conditions / Gastroesophageal junction adenocarcinoma / Houston, United States
Clinical trials for Gastroesophageal junction adenocarcinoma investigate a range of treatment strategies and patient populations.
28 total trials for this combination
Showing top 10 of 28 trials
Trials
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT03170960 | Study of Cabozantinib Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors | ACTIVE_NOT_RECRUITING | PHASE1 |
| NCT06324357 | Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread | RECRUITING | — |
| NCT04140526 | Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC | ACTIVE_NOT_RECRUITING | PHASE1/PHASE2 |
| NCT05111626 | Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab for FGFR2b Overexpressed Untreated Advanced Gastric and Gastroesophageal Junction Cancer. | ACTIVE_NOT_RECRUITING | PHASE3 |
| NCT05334069 | Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection | RECRUITING | — |
| NCT04152499 | Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (KL264-01) | ACTIVE_NOT_RECRUITING | PHASE1/PHASE2 |
| NCT07090499 | A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors | RECRUITING | PHASE1 |
| NCT01196390 | Radiation Therapy, Paclitaxel, and Carboplatin With or Without Trastuzumab in Treating Patients With Esophageal Cancer | COMPLETED | PHASE3 |
| NCT04683939 | Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy Trial of BNT141 in Patients With Unresectable or Metastatic CLDN18.2-positive Gastric, Pancreatic, Ovarian and Biliary Tract Tumors | TERMINATED | PHASE1/PHASE2 |
| NCT06324357 | Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread | RECRUITING | — |